TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05264571

Intervention type: DIAGNOSTIC_TEST
Intervention: calscreener
Description: The calscreener (SYMCEL®) is a new diagnostic tool to rapidly identify the presence of pathogens in biological samples based on micrometabolic activity detection. All living cells produce heat by the chemical and physical processes of life; by monitoring the heat flow over time (J/s, W) a significant amount of information can be obtained regarding the biological system.

Intervention type: OTHER
Intervention: Metabolic profile
Description: The cal screener allows the measure of metabolic activity of pathogens directly from a sample (here, the peritoneal fluid).~The heat production will be compared between peritoneal fluid, with or without addition of bacteria

Intervention type: OTHER
Intervention: optical microscopy
Description: To explain the metabolic activity, growth and yeast-to-hyphae transition will be analysed using optical microscopy and conventional culture

Intervention type: OTHER
Intervention: RTqPCR
Description: To explain the metabolic activity, level of expression of 5 Candida albicans virulence genes (UME6, ALS3, SFL2, HWP1 and ECE1) will be address and compared between peritoneal fluid.
Study: NCT06116877

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported overdenture
Description: mandibular 2-implant retained overdenture of non-modified printable acrylate resins base material with Zirconium oxide nanoparticles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant supported overdenture
Description: mandibular 2-implant retained overdenture of non-modified printable acrylate resins base material with Zirconium oxide nanoparticles
Study: NCT06014554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-risk subgroup
Description: Self-managed exercise programme.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium-risk subgroup
Description: Education, goal-orientated mobility programme, and enhanced discharge planning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-risk subgroup
Description: Education, enhanced assessment, orientation, and goal-orientated activities of daily living training programme.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Usual care entails physiotherapy and occupational therapy from the day after surgery to the point of discharge, with a focus on discharge planning and sufficient recovery of activities of daily living and mobility for safe return to prefracture residence.
Study: NCT05837481

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: Guided meditation utilizing breath awareness, body scan and visualization techniques
Study: NCT05338073

Intervention type: DIAGNOSTIC_TEST
Intervention: Known 3Dx Test
Description: Cancer tissue is cultured and treated with a panel of FDA approved chemotherapy and targeted therapies at a range of doses. Cell growth and phenotypes are measured to determine which treatment or treatment combinations would yield the best results for a patient. Test results are compared to actual patient outcomes collected at 3, 6, 9, and 12 months post tissue collection to determine the predictive power of the Known 3Dx Test
Study: NCT05444387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb loading
Description: 1 lb. external weight will be wrapped around both wrists during partial body weight support treadmill training. The partial body weight support treadmill training will be given for a maximum of 30 minutes and will finish earlier if the child asked to stop, or if the child stopped stepping. Body weight support will be systematically reduced, walking speed will be progressively increased over the training period, upright standing posture will be emphasized and normal kinematic components of the gait cycle will be facilitated during the training session. The training protocol for the current study will consist of 2 training sessions per weeks with at least one day in between and will last for 6 weeks.
Study: NCT05944692

Intervention type: DEVICE
Intervention: Tripolar electroencephalography
Description: We will record physiological signals with the tripolar electroencephalography

Intervention type: DEVICE
Intervention: Tripolar electroencephalography
Description: We will record physiological signals with the tripolar electroencephalography
Study: NCT04330755

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Levosimendan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levosimendan
Description: Levosimendan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Magnesium Sulfate
Study: NCT04258332

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High Salt Diet
Description: Patients will be randomized to be on a high salt diet for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High Salt Diet
Description: Patients will be randomized to be on a high salt diet for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low Salt Diet
Description: Patients will be randomized to be on a low salt for 7 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Low Salt Diet
Description: Patients will be randomized to be on a low salt for 7 days.
Study: NCT05387915

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo reduced dose radiation therapy
Study: NCT05225649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Change Intervention
Description: Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
Study: NCT06154590

Intervention type: DRUG
Intervention: Method(s)1 Attribution
Description: Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)

Intervention type: DRUG
Intervention: Method(s)1 Attribution
Description: Intervention(s): Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use the Adverse Event Dose Units- Indicate the dosing units (e.g., mg) administered to the patient. TAC, Reporting Group: Participants with Disease, Description: Presence of Disease as Defined by positive reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)

Intervention type: DRUG
Intervention: Method(s)2 Attribution,
Description: Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)

Intervention type: DRUG
Intervention: Method(s)2 Attribution,
Description: Intervention(s): -Attribution defines the relationship between the adverse event and the investigational agent(s)/intervention. Assign the appropriate category code of attribution Codes: 1-5, Descriptor, Unrelated, Unlikely, Possible, Probable, Definite.~Definitions: Use Adverse Events. Dose Units- Indicate the dosing units (e.g., mg) administered to the patient TAC. Reporting Group: Participant without Disease, Description: Absence of Disease as defined by negative reference test.~Dosage Form: 1mg Anastrozole, given once daily. 20 mg NOLVADEX (tamoxifen citrate) tablet given once daily, (the 20 mg NOLVADEX (tamoxifen citrate) tablet is bioequivalent to the 10 mg NOLVADEX. (tamoxifen citrate) tablets.)
Study: NCT06517290

Intervention type: OTHER
Intervention: Non applicable
Description: Non applicable

Intervention type: OTHER
Intervention: Non applicable
Description: Non applicable
Study: NCT05112640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSORB: subcuticular stapling device
Description: Under the skin stapling device that delivers absorbable staples

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular monocryl suture manufactured by Ethicon
Description: Under the skin suture placed by hand
Study: NCT06481631

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The PEN-3 Intervention Model
Description: The PEN-3 Model is a sociocultural model for planning and assessing participant behavior within the context a cultural phenomenon. It will be used to assess intervention impact on patient-clinical linkages in the Mississippi Delta.
Study: NCT04849897

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Virtual Reality Guided Imagery
Description: Platform and VR Goggles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Audio Only Guided Imagery
Description: Audio Recordings of Guided Imagery via an iPAD
Study: NCT04845841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080) treatment A
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080) treatment A
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080) treatment B
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elinzanetant (BAY3427080) treatment B
Description: Single oral dose
Study: NCT05637476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional strength training of hip abductors
Description: Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Pelvic drop.~2. Single leg -bridge.~3. Side-lying hip abduction with hip internal rotation.~4. Lateral step-up.~5. Standing hip abduction on stance or swing leg with extra resistance .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A selected physical therapy exercise program
Description: Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Strength dorsiflexors of the ankle-using rubber band.~2. Eccentric calf exercise (calf raise) .~3. Balance and proprioceptive exercise using wobble boards.~4. Stretch planter flexors (three sets of thirty repetitions, thirty seconds rest in between, three times per week)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A selected physical therapy exercise program
Description: Every participant will perform three sets of fifteen repetitions, fifteen seconds rest in between, three times per week for the following exercises:~1. Strength dorsiflexors of the ankle-using rubber band.~2. Eccentric calf exercise (calf raise) .~3. Balance and proprioceptive exercise using wobble boards.~4. Stretch planter flexors (three sets of thirty repetitions, thirty seconds rest in between, three times per week)
Study: NCT05499234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolantin
Description: If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolantin
Description: If VAS score is more than 4 even after additional dose, use dolantin 1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: If VAS score is more than 4 even after dolantin 1 mg/kg, 10 mg/kg paracetamol IV
Study: NCT05345782

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MARCAINE AND BETAMETHAZONE 1
Description: Laparoscopic Hypo gastric Neural Plexus Block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MARCAINE AND BETAMETHAZONE 2
Description: Laparoscopic Combined Hypo gastric Neural Plexus Block and Uterosacral Nerve Block
Study: NCT05848401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biosound Therapy System
Description: Biosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content.
Study: NCT06167473

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-mesenchymal stem cells
Description: Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-mesenchymal stem cells
Description: Different dosage of umbilical cord-mesenchymal stem cells through peripheral vein
Study: NCT04969874

Intervention type: OTHER
Group type: OTHER
Intervention: Remote follow-up
Description: The feeling of swallowing will be assessed at the end of the stay at the rehabilitation center, which corresponds to the first visit, and then every month for 5 months during remote interviews and on discharge with the Deglutition Handicap Index (DHI), a self-assessment questionnaire for the swallowing handicap.~The quality of life will be assessed at the firs visit and 6 months after using the EORTC QLQ 30 quality of life scale and the H\&N annex, a self-assessment questionnaire on the quality of life for people with cancer of the head and neck.~The satisfaction of users and the interest of city health professionals in the use of the MAX Educ tool as part of a monthly monitoring will be collected via the TUQ questionnaire, through the MAX platform at Month 6.
Study: NCT06293547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Silber Diamine Fluoride, a colorless, odorless alkaline solution, effectively halts carious lesions in various populations, including children and elderly patients, or those averse to invasive treatments. Its high fluoride content facilitates remineralization, caries arrest, and prevention. SDF application is simple, non-invasive, cost-effective, and does not stain intact enamel, making it suitable for treating dentin hypersensitivity. Its ease of use is advantageous for children, patients with special needs, and the elderly. Particularly beneficial for high-risk patients with salivary dysfunction or multiple carious lesions, SDF offers potential in pediatric dentistry and community oral health by streamlining procedures, requiring rapid application without sharp instruments or anesthesia.
Study: NCT04450953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone 50mg/day (cross over design)
Description: Eplerenone 50mg/day for 6 months followed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone 50mg/day (cross over design)
Description: Eplerenone 50mg/day for 6 months followed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Period without eplerenone (cross over design)
Description: 6-month period without eplerenone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Period without eplerenone (cross over design)
Description: 6-month period without eplerenone
Study: NCT06559332

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Risk-based CAD management
Description: Patients will not undergo routine coronary angiography prior to TAVI. For patients without known atherosclerotic cardiovascular disease, a calcium score will be derived from the available routine CT and in case of a score \>100, statin treatment of at least moderate intensity is recommended.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Invasive coronary angiography
Description: Routine invasive coronary angiography prior to TAVI. PCI recommended for coronary diameter stenosis of ≥ 80% (visual angiographic assessment) in coronary segments with a reference vessel diameter of at least 2.5 mm. Timing of PCI at the operators' discretion.
Study: NCT05032378

Intervention type: BEHAVIORAL
Intervention: Kinesthetic Awareness Training
Description: One physical or occupational therapy session per week for 8 weeks during which the participant with disordered movement will attempt to perform desired movements while wearing the KAT device

Intervention type: BEHAVIORAL
Intervention: Provision of KAT-assisted physical or occupational therapy
Description: Physical or occupational therapy professionals will provide one KAT-assisted therapy session per week for 8 weeks to one or more participants with movement disorder.
Study: NCT05532800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS002
Description: JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
Study: NCT05532813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment taken
Description: Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment taken
Description: Treatment (Metformin or placebo) will be administered orally and titrated following the same guideline that metformin in diabetic patient: start with a daily dose of 500 mg twice a day, given during or after meals; then increase to 1000 mg twice a day after a week. If digestive tolerance is good, treatment will be increased to a maximum of 1000 mg three times a day i.e. 3000 mg/day after another week.
Study: NCT04975243

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleMax Pro Plus 755nm and 1064nm laser system
Description: The GentleMax Pro Plus is a 755nm and 1064nm laser system. The GentleMax Pro PlusTM is indicated for stable long-term or permanent hair reduction using varying spot sizes and fluences.
Study: NCT05644652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physical therapy program
Description: it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~* Flexibility exercises to restore joint mobility of soft tissues.~* Static and dynamic balance exercises~* Functional strengthening exercises.~* Functional gait training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physical therapy program
Description: it will be applied for for 60 min weekly for 3 successive months in the form of three sets of exercises (20 minutes each) as follows:~* Flexibility exercises to restore joint mobility of soft tissues.~* Static and dynamic balance exercises~* Functional strengthening exercises.~* Functional gait training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking
Description: it will be conducted according to the guidelines of the International Nordic Walking Federation
Study: NCT05283044

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: biopsy liquid
Description: Patient performs a blood test at treatment baseline
Study: NCT04905381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: This arm receives usual care (control group)
Study: NCT06353308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sexual Violence Prevention
Description: The intervention included a game, five short videos, two posters, and five online quizzes, which were provided with a frequency of two posts per week and a final real-time online workshop. Materials included content on the spectrum of gender and sexual identities and orientations, gender and sexual roles, consent and communication, body positivity and self-acceptance, sexual pleasure and desire, as well as risky sexual behavior associated with dating app use and the legal issues and risks of sexual assault, such as precautionary steps and available resources.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sexual health intervention
Description: This general online sexual health education consisted of online videos, quizzes and game that covered a wide range of diverse topics on love, sex and relationships such as healthy and respectful relationships, body self-esteem, sexual identity and orientation, sexual rights and decision making, in addition to the conventional focus on sexual dysfunction and disease aversion.
Study: NCT05996692

Intervention type: OTHER
Intervention: Evaluation of adherence to walking prescriptions
Description: Adherence to walking prescriptions was evaluated according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.

Intervention type: OTHER
Intervention: Evaluation of adherence to walking prescriptions
Description: Adherence to walking prescriptions was evaluated according to a specific criterion (walking at least 30 min, in bouts of 15 min, with a small rest between bouts, twice a week, over a minimum of six consecutive weeks) based on previous recommendations.
Study: NCT05507996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant adeno-associated virus administration
Description: The investigational medical product will be injected from 1E12 GC/kg to 1E14 GC/kg.
Study: NCT06263699

Intervention type: PROCEDURE
Intervention: ROM measurement of the MCP and PIP joints in digits 4 and 5
Description: standardised picture of the hand in maximal active extension, with the back of the hand positioned on the table's surface
Study: NCT05504434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-use gastroscope
Description: Adults patients are treated with a single use gastroscope instead of a reusable gastroscope
Study: NCT04905381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LENA Star Program sessions
Description: LENA Start is an evidence-based community program designed to engage families and help them learn how to increase conversation with their children during the first few years of life.